Antipsychotic gets nod for second indication

May 7, 2007

Janssen has received word from the FDA giving it the green light to market Invega for long-term maintenance treatment of schizophrenia.

Antipsychotic gets nod for second indicationJanssen has received word from the FDA giving it the green light to market Invega for long-term maintenance treatment of schizophrenia. The atypical antipsychotic drug was previously approved in December 2006 for acute (short-term) treatment of the illness. The drug provided a significant benefit in delaying the time to relapse of symptoms of schizophrenia in a long-term efficacy study on which the FDA based its approval. The once-daily extended-release tablets contain paliperidone, the active metabolite of risperidone.

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, click here.